Malignant Melanoma | Access and Reimbursement | US | 2016

Combination therapies are transforming the malignant melanoma treatment landscape, raising the efficacy bar for emerging therapies. However, combination therapies have increased the cost of malignant melanoma treatment and drug manufacturers are under increasing pressure to justify the value of their therapy. In order to optimize market access, manufacturers need to understand the reimbursement dynamics in this market (e.g. the impact of payer-imposed restrictions, risk-sharing agreements, and patient assistance programs) and draw on insights from the successes and setbacks of current key malignant melanoma brands.

Login to access report